An antidote for Staphylococcus aureus pneumonia?

Mostrar otras versiones (1)

Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of bacterial infections in the United States. Severe invasive MRSA infections, which include pneumonia, are difficult to treat because the bacteria are resistant to antibiotics. A new report now shows that immunization against α...

Descripción completa

Detalles Bibliográficos
Autores principales: DeLeo, Frank R., Otto, Michael
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 2008
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2271020/
https://www.ncbi.nlm.nih.gov/pubmed/18268043
http://dx.doi.org/10.1084/jem.20080167
_version_ 1782151790551105536
author DeLeo, Frank R.
Otto, Michael
author_facet DeLeo, Frank R.
Otto, Michael
author_sort DeLeo, Frank R.
collection PubMed
description Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of bacterial infections in the United States. Severe invasive MRSA infections, which include pneumonia, are difficult to treat because the bacteria are resistant to antibiotics. A new report now shows that immunization against α-hemolysin (Hla), a cytolytic toxin secreted by most S. aureus strains, protects mice against lethal pneumonia. This finding represents the first successful vaccine strategy for the treatment of staphylococcal pneumonia.
format Text
id pubmed-2271020
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-22710202008-08-18 An antidote for Staphylococcus aureus pneumonia? DeLeo, Frank R. Otto, Michael J Exp Med Commentaries Methicillin-resistant Staphylococcus aureus (MRSA) is the leading cause of bacterial infections in the United States. Severe invasive MRSA infections, which include pneumonia, are difficult to treat because the bacteria are resistant to antibiotics. A new report now shows that immunization against α-hemolysin (Hla), a cytolytic toxin secreted by most S. aureus strains, protects mice against lethal pneumonia. This finding represents the first successful vaccine strategy for the treatment of staphylococcal pneumonia. The Rockefeller University Press 2008-02-18 /pmc/articles/PMC2271020/ /pubmed/18268043 http://dx.doi.org/10.1084/jem.20080167 Text en Copyright © 2008, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Commentaries
DeLeo, Frank R.
Otto, Michael
An antidote for Staphylococcus aureus pneumonia?
title An antidote for Staphylococcus aureus pneumonia?
title_full An antidote for Staphylococcus aureus pneumonia?
title_fullStr An antidote for Staphylococcus aureus pneumonia?
title_full_unstemmed An antidote for Staphylococcus aureus pneumonia?
title_short An antidote for Staphylococcus aureus pneumonia?
title_sort antidote for staphylococcus aureus pneumonia?
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2271020/
https://www.ncbi.nlm.nih.gov/pubmed/18268043
http://dx.doi.org/10.1084/jem.20080167
work_keys_str_mv AT deleofrankr anantidoteforstaphylococcusaureuspneumonia
AT ottomichael anantidoteforstaphylococcusaureuspneumonia
AT deleofrankr antidoteforstaphylococcusaureuspneumonia
AT ottomichael antidoteforstaphylococcusaureuspneumonia

Ejemplares similares